Skip to main content
Clinical Trials/ACTRN12615001238561
ACTRN12615001238561
Completed
未知

To determine the feasibility of cardiac MRI, echocardiography and serum biomarkers in detecting both early and later cardiac dysfunction in cancer patients after exposure to chemotherapy and/or radiotherapy.

iverpool Hospital0 sites44 target enrollmentNovember 12, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Cardiac dysfunction
Sponsor
iverpool Hospital
Enrollment
44
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 12, 2015
End Date
September 2, 2019
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
iverpool Hospital

Eligibility Criteria

Inclusion Criteria

  • Cohort A – breast cancer patients
  • (i) Aged greater than or equal to 18 years or older
  • (ii) Histologically confirmed diagnosis of invasive breast carcinoma
  • (iii) Receiving any anthracycline\-containing breast cancer treatment regimen, including any adjuvant trastuzumab therapy AND going on to receive adjuvant left breast \+/\- loco\-regional nodal radiotherapy, OR
  • (iv) Receiving adjuvant left breast \+/\- loco\-regional nodal radiotherapy alone (without chemotherapy).
  • Acceptable radiotherapy regimens for Cohort A patients include:
  • a)50Gy in 25 daily fractions \+/\- 10\-16Gy tumour bed boost, over 5\-6 weeks
  • b)42\.4Gy in 16 daily fractions \+/\- 10Gy tumour bed boost, over 3\-4 weeks
  • Cohort B – Non Hodgkin (NHL) Hodgkin lymphoma (HL) and leukaemia patients
  • (i) Aged greater than or equal to 18 years or older

Exclusion Criteria

  • (i) any contraindication to cardiac MRI (i.e. shrapnel, metallic implants/clips, pacemaker or defibrillator);
  • (ii) severe claustrophobia;
  • (iii) an estimated glomerular filtration rate of less than 50 mL/min/1\.732;
  • (iv) pregnancy or breast feeding;
  • (v) documented distant metastases from their known primary cancer;
  • (vi) patients receiving cancer treatment with palliative intent
  • (vii) planned or current use of other targeted biological therapies that can potentially cause cardiotoxicity (i.e. lapatinib)
  • (viii) Pre\-existing symptomatic Heart Failure (NYHA Class III or IV).
  • (ix) Recent acute coronary syndrome (myocardial infarction, unstable angina) within the last six months
  • (x) Recent coronary revascularization (percutaneous coronary intervention or coronary bypass surgery) within six months

Outcomes

Primary Outcomes

Not specified

Similar Trials